Repertoire Immune Medicines
Repertoire Immune Medicines is dedicated to decoding the immune system to develop programmable immune medicines. Their proprietary DECODE platform provides insights into the immune synapse, enabling the design of targeted therapies for cancer, autoimmune diseases, and infectious diseases. The company operates from Cambridge, Massachusetts, and Zurich, Switzerland, with a mission to improve health outcomes through innovative immune-based treatments.
Industries
Nr. of Employees
medium (51-250)
Repertoire Immune Medicines
One Kendall Square, Building 1400W, 5th Floor, Cambridge, MA 02139
Products
Immune decoding platform
A research platform that provides comprehensive insights into the immune synapse to enable discovery of molecular codes used to program immune responses for therapeutic design.
Immune decoding platform
A research platform that provides comprehensive insights into the immune synapse to enable discovery of molecular codes used to program immune responses for therapeutic design.
Services
Discovery-stage and preclinical development services focused on designing targeted immune therapeutics for oncology, autoimmune, and infectious disease indications.
Application of an immune decoding platform to identify immune-targeting codes and inform rational therapeutic design.
Discovery-stage and preclinical development services focused on designing targeted immune therapeutics for oncology, autoimmune, and infectious disease indications.
Application of an immune decoding platform to identify immune-targeting codes and inform rational therapeutic design.
Expertise Areas
- Immune repertoire analysis and immune-synapse biology
- T-cell receptor engineering
- Oncology therapeutic development
- Autoimmune disease therapeutic development
Key Technologies
- Immune synapse profiling
- Immune repertoire analysis
- T-cell receptor engineering
- Bispecific therapeutic design
News & Updates
On June 4, 2025, Repertoire announced the appointment of Robert Andtbacka as Chief Medical Officer and progress in their TCR bispecific development.
On June 4, 2025, Repertoire announced the appointment of Robert Andtbacka as Chief Medical Officer and progress in their TCR bispecific development.